Rise and shine. Another day, another deadline, or another bunch of meetings, or another project to complete. It's always something. So to help you along, we've gathered a few items. Grab the coffee or the tea and catch up. Have a good one...
A Nigerian court adjourned legal proceedings against Pfizer, Agence France-Presse reports. A criminal case was adjourned a criminal case until Feb. 4 due to the absence of the judge and three of Pfizer's Nigerian employees, who were summoned by the the court, were also absent at the hearing. Las month, the court had issued arrest warrants for them for ignoring earlier summons. Separately, the Kano state high court on Monday adjourned the civil case against Pfizer to March 3 when the prosecution and the defence would be expected to argue on the court's jurisdiction in the matter. The charges stem from a controversial clinical trial of Pfizer's meningitis drug, Trovan, that was carried out in the northern Nigerian city of Kano in 1996. The government alleges Pfizer officials played crucial roles in the clinical trial, which resulted in the deaths of meningitis patients.
The nation's largest pediatricians' group wants ABC to cancel the first episode of a new series because it perpetuates the myth that vaccines can cause autism, The New York Times reports. ABC's new drama, ''Eli Stone,'' debuts on Thursday and features a lawyer who argues in court that a flu vaccine made a child autistic. His client, an exec at the fictional vaccine maker, didn't allow his own child to get the shot. A jury offers the exec a big award. The American Academy of Pediatrics says: ''A television show that perpetuates the myth that vaccines cause autism is the height of reckless irresponsibility."
Data from ongoing colon cancer therapy studies could shift the cancer drug market, analysts say, as some drugs appear more effective at treating patients who have the K-ras gene, which is typically associated with cancer, The Boston Globe notes. In an investor note, Rodman & Renshaw analyst Michael King writes that Amgen's Vectibix, ImClone's Erbitux, and OSI Pharma's Tarceva could gain broader use based on new data. The colon cancer treatments are part of the ongoing attention given to the K-ras gene and info showing it's a good determinant of how well a patient will respond to the class of drugs called EGF receptor inhibitors.
One other thing, we initially forgot to note that Amylin Pharmaceuticals reported a widened fourth-quarter loss after Monday's market close but surprised investors with stronger-than-expected revenue and sales of its Byetta injection for type II diabetes. You can read more in TheStreet.com.